An Innovative, Closed, CAR T-Cell Therapy Platform Process to Streamline Manufacturing Approaches with Great Predictability

摘要

Golovina described recent developments at WuXi Advanced Therapies, a unit within WuXi AppTec that specializes in developing and manufacturing cell and gene therapies (CGTs). Until recently, the Advanced Therapies business operated over three sites atthe US Navy Yard in Philadelphia, PA. Those facilities focus on CGT clinical manufacturing, commercial manufacturing for autologous and allogeneic cell therapies, and late-stage and commercial production of viral vectors and gene-mediated cell therapies,respectively. But this year, WuXi added a fourth facility, also in the Navy Yard, that provides analytical services for advanced therapies and standard biologies. Golovina explained that the fourth site will enable her company to increase its testing capacity significantly. Together, the four sites offer clients integrated CGT solutions.